CORRESP Filing
Processa Pharmaceuticals, Inc.
Date: Aug. 8, 2025 · CIK: 0001533743 · Accession: 0001493152-25-011773
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39531
Referenced dates: August 6, 2025
Letter
Processa Pharmaceuticals, Inc.
August 8, 2025
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F. Street, N.E.
Washington, D.C. 20549
Attention: Mr. Chris Edwards
Mr. Joe McCann
Re: Processa Pharmaceuticals, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed July 31, 2025
File No. 001-39531
This letter is in response to the comment of the Staff (the " Staff ") of the Securities and Exchange Commission (the " Commission "), as set forth in your letter dated August 6, 2025 regarding the preliminary proxy statement filed by Processa Pharmaceuticals, Inc. (the " Company ") with the Commission on July 31, 2025. For convenience, the full text of the Staff's comment is set forth below in bold and italics, followed by the Company's response.
Preliminary Proxy Statement on Schedule 14A
General
1. Please revise the preliminary proxy statement to fill in the number of authorized shares in proposal number 1 and the reverse stock split ratios in proposal number 2.
Response: The Company has revised the preliminary proxy statement to fill in the number of authorized shares in proposal number 1 and the reverse stock split ratios in proposal number 2, as requested.
If you have any questions or require any additional information in connection with the filing of the revised preliminary proxy statement, please contact me at (772) 453-2899.
Sincerely,
/s/
Russell Skibsted
Show Raw Text
CORRESP 1 filename1.htm Processa Pharmaceuticals, Inc. August 8, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Mr. Chris Edwards Mr. Joe McCann Re: Processa Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 31, 2025 File No. 001-39531 This letter is in response to the comment of the Staff (the " Staff ") of the Securities and Exchange Commission (the " Commission "), as set forth in your letter dated August 6, 2025 regarding the preliminary proxy statement filed by Processa Pharmaceuticals, Inc. (the " Company ") with the Commission on July 31, 2025. For convenience, the full text of the Staff's comment is set forth below in bold and italics, followed by the Company's response. Preliminary Proxy Statement on Schedule 14A General 1. Please revise the preliminary proxy statement to fill in the number of authorized shares in proposal number 1 and the reverse stock split ratios in proposal number 2. Response: The Company has revised the preliminary proxy statement to fill in the number of authorized shares in proposal number 1 and the reverse stock split ratios in proposal number 2, as requested. If you have any questions or require any additional information in connection with the filing of the revised preliminary proxy statement, please contact me at (772) 453-2899. Sincerely, /s/ Russell Skibsted Russell Skibsted Chief Financial Officer